N Value
Male, n (%) 30 19 (63%)
Age at baseline visit (years old), median (IQR) 30 64 (17)
Duration of follow-up (months), median (IQR) 30 21 (37)
Past medical history
Personal history of allergy or atopic conditions, n (%) 30 6 (20%)
- Urticaria, n (%) 0 (0%)
- Atopic dermatitis, n (%) 1 (3%)
- Asthma, n (%) 2 (7%)
- EENT atopy, n (%) 1 (3%)
- Food allergy, n (%) 2 (7%)
- Drug allergy, n (%) 0 (0%)
Personal history of autoimmune diseases, n (%) 30 0 (0%)
Familial history of AE, n (%) 30 4 (13%)
Familial history of allergy or atopic conditions, n (%) 30 5 (17%)
- Urticaria, n (%) 0 (0%)
- Atopic dermatitis, n (%) 0 (0%)
- Asthma, n (%) 3 (10%)
- EENT atopy, n (%) 2 (7%)
- Food allergy, n (%) 0 (0%)
- Drug allergy, n (%) 0 (0%)
Incriminated treatment
Therapeutic class(es) 30
- ACEi alone, n (%) 25 (83%)
- ACEi + ARBs, n (%) 1 (3%)
- ACEi + DPP-4i, n (%) 4 (13%)
Duration of exposure (total in case of multiple exposures) (months), median (IQR) 26 23 (103)
Characteristics of AE attack - onset
Number of attacks, median (IQR) 29 2 (2)
Time span between first and last attacks (or first attack and consultation) (months), median (IQR) 30 2 (20)
Time of day of attack onset 24
- Attacks preferentially occur in the evening or at night (or are noticed when waking up), n (%) 6 (25%)
- Attacks preferentially occur in the morning or the afternoon, n (%) 8 (33%)
- No preferential time of day identified, n (%) 10 (42%)
Presence of prodromes, n (%) 29 1 (3%)
Triggering factor, n (%) 30 3 (10%)
Characteristics of AE attack - plateau
Affected sites 30
- Lips, n (%) 15 (50%)
- Tongue, n (%) 14 (47%)
- Uvula, n (%) 3 (10%)
- Oral cavity (excluding lips, tongue and uvula), n (%) 7 (23%)
- Throat (pharynx, larynx), n (%) 9 (30%)
- Face (excluding lips), n (%) 3 (10%)
- Digestive tract, n (%) 0 (0%)
- Genitalia, n (%) 0 (0%)
- Upper limbs, n (%) 0 (0%)
- Lower limbs, n (%) 0 (0%)
Cutaneous symptoms, n (%) 30 1 (3%)
- Urticaria, n (%) 0 (0%)
- Pruritus, n (%) 1 (3%)
ENT symptoms, n (%) 30 10 (33%)
- Dyspnea, n (%) 4 (13%)
- Dysphonia, n (%) 7 (23%)
- Dysphagia, n (%) 5 (17%)
Digestive symptoms, n (%) 30 0 (0%)
Characteristics of AE attack - resolution
Occurrence of attacks resolving without treatment, n (%) 30 9 (30%)
Occurrence of attacks resolving <24h without treatment, n (%) 30 8 (27%)
Duration of attacks without treatment (hours), median (IQR) 9 24 (42)
Treatments of attacks
Antihistamines, n (%) 30 19 (63%)
- effective treatment, n (%) 19 1 (5%)
Corticosteroids, n (%) 30 18 (60%)
- effective treatment, n (%) 18 1 (6%)
Adrenalin, n (%) 30 3 (10%)
- effective treatment, n (%) 3 0 (0%)
Tranexamic acid, n (%) 30 10 (30%)
- effective treatment, n (%) 10 7 (70%)
Bradykinin B2-receptor antagonist (icatibant), n (%) 30 19 (63%)
- effective treatment, n (%) 19 15 (79%)
Human or recombinant C1-INH concentrate, n (%) 30 4 (13%)
- effective treatment, n (%) 4 3 (75%)
Upper airway control procedures, n (%) 30 0 (0%)
Biological characteristics
Low CH50 levels, n (%) 30 0 (0%)
Low C4 levels, n (%) 30 0 (0%)
Low C1-INH levels, n (%) 30 0 (0%)
Low C1-INH activity, n (%) 30 0 (0%)
High IgE levels, n (%) 8 4 (50%)
High tryptase levels, n (%) 13 1 (7%)
Hyper-eosinophilia, n (%) 27 2 (7%)
Abnormal TSH, n (%) 20 0 (0%)
Positive anti-thyroperoxydase and/or anti-thyroglobulin antibodies, n (%) 15 0 (0%)